Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 3:54 AM
Ignite Modification Date: 2025-12-26 @ 2:43 AM
NCT ID: NCT02232802
Description: None
Frequency Threshold: 0
Time Frame: Throughout the study: day 1 (pre-dose,0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16h), Day 2 (24 and 36h), and post-study follow-up. Follow-up assessments were classified as 'End of study assessments'. They were performed on Day 2, 36 h post-dose, prior to discharging the subject.
Study: NCT02232802
Study Brief: Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Enoxaparin Sodium Chemi Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions. Enoxaparin Sodium: comparison of bioavailability of generic Enoxaparin Sodium and Clexane 0 None 1 46 7 46 View
Clexane Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions. Enoxaparin Sodium: comparison of bioavailability of generic Enoxaparin Sodium and Clexane 0 None 1 45 5 45 View
Serious Events(If Any):

Serious Events

Term Type Organ System Vocab View
Fibrous dysplasia SYSTEMATIC_ASSESSMENT Congenital, familial and genetic disorders MedDRA 17.0 / 17.1 View
Cellulitis SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 17.0 / 17.1 View
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 17.0 / 17.1 View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 17.0 / 17.1 View
Syncope SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA 17.0 / 17.1 View
Abdominal pain upper SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 17.0 / 17.1 View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA 17.0 / 17.1 View
Eczema SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA 17.0 / 17.1 View
Back pain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 17.0 / 17.1 View
Ligament sprain SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA 17.0 / 17.1 View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 17.0 / 17.1 View